Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT07197580
Overview
Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator's choice of monotherapy
Sponsor
Telix PharmaceuticalsPhase
Phase 3
Contacts
Prson Gautam, PhD
prson.gautam@telixpharma.com
19196508158
ClinicalTrials.gov
NCT07197580Drug / Compound
Patient Education
Patient education not yet provided.
Publications
Publications not yet provided.
Locations
Loading…
Help us improve your experience